Femasys (NASDAQ:FEMY – Get Free Report) and Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Earnings & Valuation
This table compares Femasys and Intelligent Bio Solutions’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $1.07 million | 21.60 | -$14.25 million | ($0.84) | -1.24 |
| Intelligent Bio Solutions | $1.26 million | 4.38 | -$10.63 million | ($38.91) | -0.05 |
Intelligent Bio Solutions has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -1,420.59% | -104.06% | -73.32% |
| Intelligent Bio Solutions | -354.86% | -210.36% | -89.33% |
Volatility and Risk
Femasys has a beta of -2.79, suggesting that its stock price is 379% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.75, suggesting that its stock price is 375% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Femasys and Intelligent Bio Solutions, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 0 | 0 | 3 | 0 | 3.00 |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
Femasys currently has a consensus target price of $11.67, indicating a potential upside of 1,021.79%. Given Femasys’ higher probable upside, research analysts clearly believe Femasys is more favorable than Intelligent Bio Solutions.
Institutional & Insider Ownership
65.3% of Femasys shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 12.3% of Femasys shares are owned by company insiders. Comparatively, 0.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Femasys beats Intelligent Bio Solutions on 8 of the 13 factors compared between the two stocks.
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
